Insider Selling: Glaukos (NYSE:GKOS) CEO Sells $42,640,200.00 in Stock

Glaukos logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Thomas Burns sold 180,000 Glaukos shares for $42.64 million, reducing his direct stake by 73.45% to 65,060 shares.
  • Glaukos reported quarterly EPS of $0.47, beating the consensus estimate of a $0.10 loss; revenue of $211.03 million was up 58% year over year and exceeded forecasts.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $218, below the stock’s reported Friday price of $237.24.
  • Interested in Glaukos? Here are five stocks we like better.

Glaukos Corporation (NYSE:GKOS - Get Free Report) CEO Thomas Burns sold 180,000 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $236.89, for a total transaction of $42,640,200.00. Following the sale, the chief executive officer directly owned 65,060 shares of the company's stock, valued at $15,412,063.40. The trade was a 73.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Price Performance

GKOS traded down $0.86 during trading on Friday, hitting $237.24. The stock had a trading volume of 1,089,557 shares, compared to its average volume of 1,904,561. Glaukos Corporation has a twelve month low of $93.78 and a twelve month high of $255.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. The stock has a 50 day simple moving average of $190.92 and a two-hundred day simple moving average of $150.09.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The business had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same period in the previous year, the company earned ($0.16) earnings per share. The business's revenue for the quarter was up 58.0% on a year-over-year basis. As a group, research analysts forecast that Glaukos Corporation will post 0.64 EPS for the current fiscal year.

Trending Headlines about Glaukos

Here are a few of the latest headlines about GKOS:

  • Positive Sentiment: Zacks Research lifted its FY2026 EPS estimate to $0.42 from a forecasted loss of $0.43, and its FY2027 estimate to $1.24 from $0.45. It also raised its FY2028 forecast to $2.24 from $1.70 and increased estimates for multiple quarters. The revisions suggest improved expectations for earnings growth, although they come from one research firm. Glaukos analyst estimates
  • Negative Sentiment: COO Joseph Gilliam sold 861 shares for about $215,000 at $250 per share, reducing his stake by 1.19%. The sale may weigh modestly on sentiment, but he still owned 71,602 shares after the transaction. Insider sale report

Wall Street Analysts Forecast Growth

A number of research firms have commented on GKOS. BTIG Research increased their price target on Glaukos from $234.00 to $252.00 and gave the company a "buy" rating in a research note on Monday. Mizuho set a $225.00 price target on Glaukos in a research note on Thursday, October 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a report on Thursday, October 15th. Needham & Company LLC increased their price objective on shares of Glaukos from $201.00 to $251.00 and gave the company a "buy" rating in a research report on Thursday, October 29th. Finally, Wells Fargo & Company lifted their target price on shares of Glaukos from $178.00 to $226.00 and gave the stock an "overweight" rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus target price of $218.00.

View Our Latest Analysis on GKOS

Hedge Funds Weigh In On Glaukos

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Glaukos in the 2nd quarter worth $1,333,318,000. Jupiter Topco LLC purchased a new stake in Glaukos during the 2nd quarter valued at about $679,614,000. Primecap Management Co. CA purchased a new stake in Glaukos during the 2nd quarter valued at about $424,969,000. Janus Henderson Group PLC grew its stake in Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock valued at $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new position in shares of Glaukos in the second quarter valued at about $92,476,000. 99.04% of the stock is owned by institutional investors and hedge funds.

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Recommended Stories

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines